JHPCY (Jiangsu Hengrui Pharmaceuticals Co) Growth Rank: 8 (As of Sep. 06, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JHPCY Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
68 GF Score
Price $20.00
GF Value $15.39
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Growth Rank?

Jiangsu Hengrui Pharmaceuticals Co JHPCY 68 Growth Rank is 8 as of Sep. 06, 2026, which is at its 10-year median of 8.00. GuruFocus rates JHPCY with a GF Score™ of 68/100 and a GF Value™ of $15.39 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Jiangsu Hengrui Pharmaceuticals Co has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Jiangsu Hengrui Pharmaceuticals Co Growth Rank Related Terms

JHPCY vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jiangsu Hengrui Pharmaceuticals Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Growth Rank falls into.


JHPCY
68GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Jiangsu Hengrui Pharmaceuticals Co (JHPCY) has a Growth Rank of 8 as of Sep. 06, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is near median its historical median of 8.00. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Growth Rank has ranged from 8.00 to 9.00.
Is Jiangsu Hengrui Pharmaceuticals Co's Growth Rank too high?
Jiangsu Hengrui Pharmaceuticals Co's current Growth Rank of 8 is near median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 9.00. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Growth Rank compare to ZTS?
Jiangsu Hengrui Pharmaceuticals Co's Growth Rank of 8 can be compared against companies in the Drug Manufacturers industry. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Growth Rank has ranged from 8.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. Jiangsu Hengrui Pharmaceuticals Co's current Growth Rank is 8, which is near median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (JHPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $15.39, compared to a current price of $20.00 — trading 30% above its estimated fair value. The current Growth Rank is 8, which is near median its 10-year median of 8.00. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (JHPCY), the current Growth Rank is 8 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be overvalued. The current stock price of $20.00 is trading 30% above its estimated GF Value™ of $15.39. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for JHPCY:

  • Growth Rank: 8 (near median its 10-year median of 8.00)
  • GF Value™: $15.39 vs. price of $20.00 (30% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
68GF Score

Get the complete analysis for JHPCY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.00
Price
$15.39
GF Value